

Resource Summary Report

Generated by [dkNET](#) on Aug 9, 2026

CD3 PE SK7 100 Tests RUO/GMP

RRID:AB_400287

Type: Antibody

Proper Citation

BD Biosciences Cat# 347347, RRID:AB_400287

Antibody Information

URL: http://antibodyregistry.org/AB_400287

Proper Citation: BD Biosciences Cat# 347347, RRID:AB_400287

Target Antigen: CD3

Host Organism: Mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD3 PE SK7 100 Tests RUO/GMP

Description: This monoclonal targets CD3

Target Organism: Human

Clone ID: clone SK7 (also known as Leu-4)

Antibody ID: AB_400287

Vendor: BD Biosciences

Catalog Number: 347347

Record Creation Time: 20250820T025509+0000

Record Last Update: 20250820T145149+0000

Ratings and Alerts

No rating or validation information has been found for CD3 PE SK7 100 Tests RUO/GMP.

No alerts have been found for CD3 PE SK7 100 Tests RUO/GMP.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tseng I, et al. (2025) Radiation Dose-Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(10), 2024.

Landi D, et al. (2025) A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. Cancer research communications, 5(3), 527.

Kishton RJ, et al. (2022) Cancer genes disfavoring T??cell immunity identified via integrated systems approach. Cell reports, 40(5), 111153.

Sun W, et al. (2022) GFI1 Cooperates with IKZF1/IKAROS to Activate Gene Expression in T-cell Acute Lymphoblastic Leukemia. Molecular cancer research : MCR, 20(4), 501.

Sun C, et al. (2020) THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells. Cancer cell, 37(2), 216.

Fedyk ER, et al. (2020) Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. British journal of clinical pharmacology, 86(7), 1314.